Table 3 Characteristics of CTC-positive patients
Patient | Menopausal status | IHC tumour type | Number of previously received treatment linesa | Metastatic site | CTC count | AR positive CTC (%) | AR localization |
|---|---|---|---|---|---|---|---|
1 | postmenopausal | HR+ HER2- | 1 | bone visceral | 101 | 84 (83) | cytoplasm/nucleus |
2 | premenopausal | HR+ HER2- | 0 | bone | 13 | 7 (54) | cytoplasm |
3 | postmenopausal | HR+ HER2- | 2 | bone visceral | 10 | 3 (30) | cytoplasm |
4 | postmenopausal | HR+ HER2- | 2 | bone | 9 | 0 (0) | – |
5 | premenopausal | TNBC | 0 | bone visceral | 8 | 1 (12) | cytoplasm |
6 | premenopausal | HR+ HER2- | 0 | bone | 7 | 7 (100) | nucleus |
7 | unknown | HR+ HER2- | 0 | unknown | 4 | 3 (75) | cytoplasm |
8 | postmenopausal | HR+ HER2- | 4 | bone visceral | 4 | 3 (75) | cytoplasm |
9 | postmenopausal | HR+ HER2- | 0 | bone | 3 | 1 (33) | cytoplasm |
10 | postmenopausal | HR+ HER2- | 7 | bone | 3 | 3 (100) | cytoplasm |
11 | postmenopausal | HR+ HER2- | 0 | visceral | 3 | 3 (100) | cytoplasm |
12 | postmenopausal | HR+ HER2- | 3 | bone visceral | 3 | 0 (0) | – |
13 | postmenopausal | HR+ HER2- | 4 | bone visceral | 3 | 0 (0) | – |
14 | postmenopausal | HR+ HER2- | 1 | bone visceral | 3 | 0 (0) | – |
15 | unknown | HR+ HER2+ | 2 | visceral | 3 | 0 (0) | – |
16 | premenopausal | HR+ HER2- | 0 | bone lymph nodes | 3 | 0 (0) | – |
17 | premenopausal | TNBC | 1 | bone visceral | 2 | 1 (50) | nucleus |
18 | postmenopausal | HR+ HER2- | 1 | bone | 2 | 0 | – |
19 | postmenopausal | HR+ HER2- | 2 | bone visceral | 2 | 0 | – |
20 | postmenopausal | HR+ HER2- | 2 | bone visceral | 2 | 0 | – |
21 | postmenopausal | TNBC | 0 | visceral | 2 | 0 | – |
22 | postmenopausal | HR+ HER2- | 2 | bone lymph nodes | 2 | 0 | – |
23 | postmenopausal | HR+ HER2- | 2 | bone | 2 | 0 | – |
24 | postmenopausal | HR+ HER2- | 1 | bone visceral | 2 | 0 | – |
25 | premenopausal | HR+ HER2- | 0 | bone | 2 | 0 | – |
26 | postmenopausal | HR+ HER2- | 1 | bone visceral | 1 | 1 (100)- | nucleus |
27 | postmenopausal | HR+ HER2- | 0 | bone visceral | 1 | 1 (100) | nucleus |
28 | postmenopausal | HR+ HER2- | 3 | bone visceral | 1 | 1 (100) | cytoplasm |
29 | postmenopausal | HR+ HER2- | 0 | Lymph nodes | 1 | 1 (100) | nucleus |
30 | postmenopausal | HR+ HER2- | 7 | Bone lymph nodes | 1 | 1 (100) | cytoplasm |
31 | postmenopausal | HR+ HER2- | 0 | visceral | 1 | 0 | – |
32 | postmenopausal | HR+ HER2- | 0 | bone visceral | 1 | 0 | – |
33 | premenopausal | TNBC | 1 | visceral | 1 | 0 | – |
34 | postmenopausal | HR+ HER2- | 0 | visceral | 1 | 0 | – |
35 | postmenopausal | HR+ HER2- | 0 | visceral | 1 | 0 | – |
36 | postmenopausal | TNBC | 1 | bone visceral | 1 | 0 | – |
37 | postmenopausal | TNBC | 2 | visceral | 1 | 0 | – |